CMS Decision Could Limit Patient Access to COVID-19 Oral Antivirals

Video

An FDA decision regarding Merck's COVID-19 oral antiviral is imminent, but a recent CMS decision could limit patient access.

With an FDA decision imminent regarding Merck's COVID-19 oral antiviral, Pharmacy Times spoke with Tom Kraus, JD, vice president of government relations at the American Society of Health-System Pharmacists, about how a recent decision by the Centers for Medicare and Medicaid Services (CMS) could limit patient access.

Kraus explained that rather than requiring payment for pharmacists providing testing, patient assessment, ordering, prescribing, and dispensing of COVID-19 oral antivirals, CMS said payment for these services is only encouraged. Because many pharmacies are already strained amid the other responsibilities during the COVID-19 pandemic, adding other responsibilities without payment could force some pharmacies to consider which services they can afford to provide.

Kraus also emphasized that if pharmacists' provider status were established on a federal level, finding complicated workarounds for payment would not be an issue. Ultimately, Kraus said, Congress should step in and designate provider status for pharmacists.

Related Videos
BillionPhotos.com - stock.adobe.com
Whole psilocybin mushroom in a clear medication capsule | Image credit: Zim - stock.adobe.com
Patient suffering from atopic dermatitis -- Image credit: Nikkikii | stock.adobe.com
Image credit: Fabio Balbi | stock.adobe.com
Image credit: Melita - stock.adobe.com
Atopic dermatitis on a patient's hand -- Image credit: Ольга Тернавская | stock.adobe.com
cropped view of man performing chest compression on dummy during cpr training class - Image credit: LIGHTFIELD STUDIOS | stock.adobe.com
Medicine law concept. Judges gavel with pills | Image Credit: Iren Moroz - stock.adobe.com
Image credit: New Africa | stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.